Blueprint Medicines Corp. (BPMC) - Cash Funds per Single Share

Under the leadership of Phil Allen, Blueprint Medicines management is ensuring flawless strategic execution. Blueprint Medicines develops selective kinase inhibitors, successfully competing with industry behemoths in the treatment of rare mutations. On GURU.Markets, the cash per share history confirms financial stability, where the value 8.87 describes the current liquidity level. This supports leadership in precision therapy through the drug Ayvakit and the development of a promising pipeline.
Comprehensive metric breakdowns and analytics for Blueprint Medicines Corp. (BPMC)

Blueprint Medicines is investing billions into the development of precision kinase inhibitors to combat oncology. By analyzing the history of cash per share, an investor assesses the company's liquidity. This indicator is calculated by dividing the total amount of free cash flow by the number of outstanding shares. The metric demonstrates the biotech's ability to fund R&D without external borrowing. An increase in this value confirms financial stability and reduces the risk of default.